

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))Docket No.
18467In Re Application of: **Lloyd S. Gray, et al.**

Application No. 10/589,216	Filing Date August 11, 2006	Examiner Unassigned	Customer No. 23389	Group Art Unit Unassigned	Confirmation No. Unassigned
-------------------------------	--------------------------------	------------------------	-----------------------	------------------------------	--------------------------------

Title:

**INHIBITING CAV3 ISOFORMS AND THE δ 25B SPLICE VARIANTS FOR THE
DIAGNOSIS AND TREATMENT OF CANCER****Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**Certificate of Transmission by Facsimile***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

October 17, 2006
(Date)

Signature of Person Mailing Correspondence

Peter I. Bernstein

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: October 17, 2006

Peter I. Bernstein
 Registration No. 43,497
 Scully, Scott, Murphy & Presser, P.C.
 400 Garden City Plaza, Suite 300
 Garden City, New York 11530
 516-742-4343

CC:

P10A/REV06

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 18467	
In Re Application Of: Lloyd S. Gray, et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/589,216	August 11, 2006	Unassigned	23389	Unassigned	Unassigned	
Title: INHIBITING CAV3 ISOFORMS AND THE δ 25B SPLICE VARIANTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
37 CFR 1.97(b)						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
37 CFR 1.97(c)						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);						
OR						
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).						

P10A/REV06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Lloyd S. Gray, et al.	Examiner:	Unassigned
Serial No:	10/589,216	Art Unit:	Unassigned
Filed:	August 11, 2006	Docket:	18467
For:	INHIBITING CAV3 ISOFORMS AND THE δ 25B SPLICE VARIANTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER		
Dated:	October 17, 2006		

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Merritt J.E. et al., "Regulation of Cytosolic Free Calcium in Fura-2-Loaded Rat Parotid Acinar Cells", *The Journal of Biological Chemistry*, 262(36):17362-17369 (1987);
2. Massie B.M., "Mibefradil: A Selective T-Type Calcium Antagonist", *Am. J. Cardiol*, 80(9A):231-321 (1997);
3. Köhler G. et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", *Nature*, 256:495-497 (1975);
4. Goding J.W., "Monoclonal Antibodies: Principles and Practice", *N.Y. Academic Press*, pp. 98-119 (1983);

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 17, 2006


Peter I. Bernstein

5. Colcher D. et al., "Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xenografts in Athymic Mice", *Methods in Enzymology*, 121:802-816 (1986);
6. Haverstick D.M. et al., "Increased Intracellular Ca^{2+} Induces Ca^{2+} Influx in Human T Lymphocytes", *Molecular Biology of the Cell*, 4:173-184 (1993); and
7. Haverstick D.M. et al., "Three Intracellular Signals for Cytotoxic T Lymphocyte-Mediated Killing", *The Journal of Immunology*, 146(10):3306-3313 (1991).

The relevance of the above-identified references has been described in the specification. A copy of the foregoing references is enclosed.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Peter I. Bernstein

Registration No.: 43,497

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE LIST OF PRIOR ART CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		Atty. Docket No. (Optional) 18467	Application Number 10/589,216
		Applicant(s) Lloyd S. Gray, et al.	
		Filing Date August 11, 2006	Group Art Unit Unassigned
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
		Merritt J.E. et al., "Regulation of Cytosolic Free Calcium in Fura-2-Loaded Rat Parotid Acinar Cells", <i>The Journal of Biological Chemistry</i> , 262(36):17362-17369 (1987)	
		Massie B.M., "Mibefradil: A Selective T-Type Calcium Antagonist", <i>Am. J. Cardiol</i> , 80(9A):231-321 (1997)	
		Köhler G. et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", <i>Nature</i> , 256:495-497 (1975)	
		Goding J.W., "Monoclonal Antibodies: Principles and Practice", <i>N.Y. Academic Press</i> , pp. 98-119 (1983)	
		Colcher D. et al., "Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xenografts in Athymic Mice", <i>Methods in Enzymology</i> , 121:802-816 (1986)	
		Haverstick D.M. et al., "Increased Intracellular Ca ²⁺ Induces Ca ²⁺ Influx in Human T Lymphocytes", <i>Molecular Biology of the Cell</i> , 4:173-184 (1993)	
		Haverstick D.M. et al., "Three Intracellular Signals for Cytotoxic T Lymphocyte-Mediated Killing", <i>The Journal of Immunology</i> , 146(10):3306-3313 (1991)	
EXAMINER /Yan Xiao/		DATE CONSIDERED 11/29/2010	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			